Li CC - Search Results

1

Quantitative Clinical Pharmacology of T-Cell Engaging Bispecifics: Current Perspectives and Opportunities.

Morcos PN, Li J, Hosseini I, Li CC. Morcos PN, et al. Among authors: li cc, li j. Clin Transl Sci. 2021 Jan;14(1):75-85. doi: 10.1111/cts.12877. Epub 2020 Nov 18. Clin Transl Sci. 2021. PMID: 32882099 Free PMC article. Review.

2

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.

Hosseini I, Gadkar K, Stefanich E, Li CC, Sun LL, Chu YW, Ramanujan S. Hosseini I, et al. Among authors: li cc. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. doi: 10.1038/s41540-020-00145-7. NPJ Syst Biol Appl. 2020. PMID: 32859946 Free PMC article.

3

Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL.

Susilo ME, Li CC, Gadkar K, Hernandez G, Huw LY, Jin JY, Yin S, Wei MC, Ramanujan S, Hosseini I. Susilo ME, et al. Among authors: li cc. Clin Transl Sci. 2023 Jul;16(7):1134-1148. doi: 10.1111/cts.13501. Epub 2023 Mar 23. Clin Transl Sci. 2023. PMID: 36908269 Free PMC article. Clinical Trial.

4

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Bender B, Li CC, Marchand M, Turner DC, Li F, Vadhavkar S, Wang B, Deng R, Lu J, Jin J, Li C, Yin S, Wei M, Chanu P. Bender B, et al. Among authors: li cc, li f, li c. Clin Transl Sci. 2024 Jun;17(6):e13825. doi: 10.1111/cts.13825. Clin Transl Sci. 2024. PMID: 38808543 Free PMC article.

5

Clinical Pharmacology of Cytokine Release Syndrome with T-cell Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies.

Radtke KK, Bender BC, Li Z, Turner DC, Roy S, Belousov A, Li CC. Radtke KK, et al. Among authors: li cc, li z. Clin Cancer Res. 2024 Nov 18. doi: 10.1158/1078-0432.CCR-24-2247. Online ahead of print. Clin Cancer Res. 2024. PMID: 39556515

6

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.

Lu D, Lu T, Stroh M, Graham RA, Agarwal P, Musib L, Li CC, Lum BL, Joshi A. Lu D, et al. Among authors: li cc. Cancer Chemother Pharmacol. 2016 Mar;77(3):459-76. doi: 10.1007/s00280-015-2931-4. Epub 2016 Jan 25. Cancer Chemother Pharmacol. 2016. PMID: 26811176 Free PMC article. Review.

7

Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time.

Netterberg I, Bruno R, Chen YC, Winter H, Li CC, Jin JY, Friberg LE. Netterberg I, et al. Among authors: li cc. CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):115-123. doi: 10.1002/psp4.12489. Epub 2020 Jan 28. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 31991070 Free PMC article.

8

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.

Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: li cc. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. J Clin Oncol. 2022. PMID: 34914545 Free PMC article. Clinical Trial.

9

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.

Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Budde LE, et al. Among authors: li cc. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.

10

Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.

Lu D, Gillespie WR, Girish S, Agarwal P, Li C, Hirata J, Chu YW, Kagedal M, Leon L, Maiya V, Jin JY. Lu D, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):401-408. doi: 10.1002/psp4.12192. Epub 2017 May 23. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28544534 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,717 results

Search Page

Filters